Utama › Kanser Pundi Kencing Bukan Invasif Otot › Ohio
Kajian klinikal Kanser Pundi Kencing Bukan Invasif Otot di Ohio
13 kajian untuk Kanser Pundi Kencing Bukan Invasif Otot sedang mencari peserta di lokasi di Ohio.
Bandar di Ohio
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- Ohio State University Comprehensive Cancer Center, Columbus
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07000084A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0122), Cincinnati
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06833073Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
- The James at Brain and Spine Hospital (OSU), Columbus
- Oregon Urology Institute, Springfield
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06995677A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- Dayton Physicians Network Urology, Centerville
- Central Ohio Urology Group, Gahanna
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06919965Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
- University Hospitals Cleveland Medical Center, Cleveland
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT05796375Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Cleveland Clinic Main Campus, Cleveland, Cleveland
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT05951179FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Cincinnati Medical Center (UCMC), Cincinnati
- The Ohio State University (OSU), Columbus
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT05614739LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- University of Cincinnati Medical Center, Cincinnati
- Central Ohio Urology Group, Gahanna
- Clinical Research Solutions - Helios Clinical Research, Middleburg Heights
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT04752722Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
- The Ohio State University, Columbus
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT07225127A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
- The Ohio State University, Columbus
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Mei 2026 · NCT05710848Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Mac 2026 · NCT07474519Blue Light Cystoscopy With Cysview® Registry
- Ohio State University Wexner Medical Center, Columbus
- Ohio State University, Columbus
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Dis 2025 · NCT02660645Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
- Site 02-017 - Central Ohio Urology Group, Gahanna
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Nov 2025 · NCT03945162Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.